Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
IBUPROFEN SODIUM vs ABSTRAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Non-selective inhibitor of cyclooxygenase (COX-1 and COX-2), decreasing prostaglandin synthesis, resulting in anti-inflammatory, analgesic, and antipyretic effects.
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Mild to moderate pain,Primary dysmenorrhea,Osteoarthritis,Rheumatoid arthritis,Fever reduction (FDA-approved OTC use),Migraine (OTC and prescription formulations)
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
200-400 mg orally every 4-6 hours, maximum 1200 mg/day; for OTC use, 200-400 mg every 6-8 hours as needed, maximum 1200 mg/day.
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
2.0-2.5 hours (terminal); no prolongation in mild hepatic impairment; increased in renal failure.
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Primarily hepatic via CYP2C9; major metabolites are hydroxylated and carboxylated derivatives, with subsequent glucuronidation.
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Renal: 90% as metabolites and conjugates, <1% unchanged; biliary/fecal: minor.
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
99% bound to albumin.
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
0.15-0.3 L/kg; distribution limited by high protein binding.
4-6 L/kg; large Vd indicates extensive tissue distribution
Oral: 80-100% (rapid absorption); Topical: negligible systemic bioavailability (<5%).
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
GFR 30-90 m L/min: no adjustment needed. GFR <30 m L/min: avoid use; if necessary, reduce dose and extend interval (e.g., 200-400 mg every 8-12 hours). Not recommended in severe renal impairment (GFR <15 m L/min).
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50% (maximum 600 mg/day). Child-Pugh C: avoid use.
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
Infants and children (≥6 months): 5-10 mg/kg per dose orally every 6-8 hours, maximum 40 mg/kg/day. For fever or pain, 5 mg/kg if temperature <102.5°F, 10 mg/kg if ≥102.5°F.
Not approved for pediatric patients <18 years; safety and efficacy not established.
Initiate at lowest effective dose (200 mg) and titrate slowly; maximum 1200 mg/day. Monitor renal function, GI bleeding risk, and drug interactions (e.g., ACE inhibitors, diuretics). Avoid chronic use if possible.
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
None formally required for ibuprofen sodium, but NSAIDs carry increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke (especially with prolonged use or in patients with cardiovascular risk factors). NSAIDs also increase risk of serious GI adverse events including bleeding, ulceration, and perforation.
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Cardiovascular risk: increased risk of thrombotic events, MI, stroke; avoid in setting of CABG surgery.,GI risk: increased risk of bleeding, ulceration, perforation; caution in patients with history of peptic ulcer disease or GI bleeding.,Renal effects: may cause renal impairment, especially in elderly, volume-depleted, or those with pre-existing renal disease.,Anaphylactoid reactions: can occur in patients without prior exposure; cross-sensitivity with aspirin.,Hepatic effects: rare severe hepatic reactions; monitor liver function.,Hypertension: can worsen blood pressure control; monitor.,Asthma: may precipitate bronchospasm in aspirin-sensitive patients.
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Hypersensitivity to ibuprofen or any NSAID,History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs,Active peptic ulcer disease or GI bleeding,Severe renal impairment (Cr Cl <30 m L/min),Severe hepatic impairment,Perioperative pain in the setting of coronary artery bypass graft (CABG) surgery,Late pregnancy (third trimester) due to risk of premature closure of ductus arteriosus
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
Avoid alcohol as it increases risk of GI bleeding. High-fat meals may slightly delay absorption but not clinically significant. St. John's Wort may reduce ibuprofen levels. No specific food restrictions.
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
First trimester: Avoid; associated with increased risk of cardiac defects and gastroschisis. Second trimester: Use with caution; limited evidence of structural anomalies. Third trimester: Contraindicated; risks include premature ductus arteriosus closure, oligohydramnios, and necrotizing enterocolitis.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
Excreted into breast milk in low amounts (M/P ratio approximately 0.01-0.02). Considered compatible with breastfeeding due to low infant dose, but avoid if infant has thrombocytopenia or bleeding diathesis.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
No specific dose adjustment required for pharmacokinetic changes in pregnancy; however, use lowest effective dose and shortest duration. Avoid in third trimester due to fetal risks. Increased renal clearance in pregnancy may reduce efficacy, but no dosing recommendations exist.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
Ibuprofen sodium is more rapidly absorbed than ibuprofen acid, leading to faster onset of analgesia (within 30 minutes). Use with caution in patients with cardiovascular disease, renal impairment, or history of GI bleeding. Avoid in late pregnancy (risk of premature ductus arteriosus closure). Monitor renal function in elderly and volume-depleted patients.
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
Take with food or milk to reduce stomach upset.,Do not exceed recommended dose (1200 mg/day OTC) or duration (10 days for pain).,Avoid alcohol while taking ibuprofen to prevent GI irritation.,Stop and seek medical attention if signs of GI bleeding (black stools, vomit with blood) occur.,Consult doctor before use if you have high blood pressure, heart disease, kidney disease, or stomach ulcers.,Do not take with other NSAIDs or aspirin without physician approval.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
"Concomitant use of Ibuprofen (a nonsteroidal anti-inflammatory drug, NSAID) and Methylprednisolone (a systemic corticosteroid) synergistically increases the risk of gastrointestinal (GI) ulceration, bleeding, and perforation due to additive inhibition of prostaglandin synthesis and mucosal protection. Additionally, Ibuprofen may potentiate the immunosuppressive effects of Methylprednisolone, elevating infection risk. This interaction can lead to serious clinical outcomes, including acute GI hemorrhage, perforation, and impaired wound healing."
"The combination of olopatadine, an antihistamine with sedative properties, and ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), may result in additive central nervous system (CNS) depression, leading to increased sedation, dizziness, and impaired psychomotor function. Ibuprofen can inhibit the metabolism of olopatadine via competition for hepatic CYP450 enzymes, potentially elevating olopatadine plasma concentrations and prolonging its systemic effects. Clinically, patients may experience exacerbated drowsiness, reduced alertness, and increased risk of falls or accidents, especially in the elderly or those with compromised hepatic function."
"Ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), can decrease the metabolism of pioglitazone, a thiazolidinedione antidiabetic agent, by inhibiting cytochrome P450 2C8 (CYP2C8) enzyme activity. This inhibition elevates plasma concentrations of pioglitazone, potentially enhancing its hypoglycemic effects and increasing the risk of adverse reactions such as edema, weight gain, and heart failure exacerbation. Clinically, concomitant use may lead to improved glycemic control but also raises concerns for dose-dependent toxicities, necessitating careful monitoring and possible dose adjustment of pioglitazone."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about IBUPROFEN SODIUM vs ABSTRAL, answered by our medical review team.
IBUPROFEN SODIUM is a NSAID that works by Non-selective inhibitor of cyclooxygenase (COX-1 and COX-2), decreasing prostaglandin synthesis, resulting in anti-inflammatory, analgesic, and antipyretic effects.. ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between IBUPROFEN SODIUM and ABSTRAL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of IBUPROFEN SODIUM is: 200-400 mg orally every 4-6 hours, maximum 1200 mg/day; for OTC use, 200-400 mg every 6-8 hours as needed, maximum 1200 mg/day.. The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between IBUPROFEN SODIUM and ABSTRAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. IBUPROFEN SODIUM is classified as Category D/X. First trimester: Avoid; associated with increased risk of cardiac defects and gastroschisis. Second trimester: Use with caution; limited evidence of structural anomalies. Third tri. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.